Valuation: Arsanis Inc

Market Cap 360M 316M 292M 268M 507M 34.74B 515M 3.49B 1.37B 17B 1.35B 1.32B 58.57B P/E 2026 *
-5.23x
P/E 2027 * -4.99x
Enterprise Value 271M 238M 220M 202M 381M 26.16B 388M 2.63B 1.03B 12.8B 1.02B 997M 44.1B EV / Sales 2026 *
28.3x
EV / Sales 2027 * 18.1x
Free-Float
92.32%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 -
Director of Finance/CFO 71 2025-08-11
President - 2025-08-11
Director TitleAgeSince
Chairman 71 2018-06-30
Director/Board Member 63 2018-09-30
Director/Board Member 65 2019-03-28
Change 5-day change 1-year change 3-year change Capi.($)
+27.91%-3.04% - - 360M
-1.65%-1.59%+52.60%+150.76% 1,051B
-1.33%-3.05%+52.04%+48.41% 609B
-0.44%+2.11%+36.99%+78.09% 450B
-0.75%+0.30%+29.77%+21.15% 330B
-1.52%-1.19%+34.46%+35.35% 284B
-1.70%-1.82%+20.99%+15.74% 263B
-0.58%+1.11%-20.18%-40.59% 223B
-0.36%+1.34%+23.46%+56.62% 198B
-0.65%+1.69%+23.40%+67.14% 167B
Average +1.91%+0.54%+28.17%+48.08% 397.23B
Weighted average by Cap. -1.15%+0.02%+37.15%+72.05%

Financials

2026 *2027 *
Net sales 9.6M 8.41M 7.78M 7.15M 13.5M 926M 13.71M 93M 36.46M 453M 36.05M 35.26M 1.56B 10.26M 8.99M 8.31M 7.65M 14.42M 989M 14.66M 99.4M 38.96M 484M 38.53M 37.69M 1.67B
Net income -95.1M -83.36M -77.05M -70.86M -134M -9.17B -136M -921M -361M -4.49B -357M -349M -15.46B -109M -95.21M -88M -80.94M -153M -10.47B -155M -1.05B -412M -5.12B -408M -399M -17.66B
Net Debt -89M -78.01M -72.11M -66.32M -125M -8.58B -127M -862M -338M -4.2B -334M -327M -14.47B -174M -153M -141M -130M -245M -16.83B -249M -1.69B -663M -8.23B -655M -641M -28.37B
Logo Arsanis Inc
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-